These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 27117691

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J, Lei M, Wu W, Feng H, Wang J, Chen S, Zhu Y, Hu S, Liu Z, Jiang C.
    Bioorg Med Chem Lett; 2016 Apr 15; 26(8):1958-62. PubMed ID: 26965867
    [Abstract] [Full Text] [Related]

  • 4. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M, Feng H, Bai E, Zhou H, Wang J, Qin Y, Zhang H, Wang X, Liu Z, Hai O, Liu J, Zhu Y.
    Org Biomol Chem; 2019 Jan 16; 17(3):683-691. PubMed ID: 30601533
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
    Zhang W, Bai H, Han L, Zhang H, Xu B, Cui J, Wang X, Ge Z, Li R.
    Bioorg Med Chem Lett; 2018 Aug 01; 28(14):2459-2464. PubMed ID: 29886021
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Zhang J, Shen L, Wang J, Luo P, Hu Y.
    Med Chem; 2014 Aug 01; 10(1):38-45. PubMed ID: 23676009
    [Abstract] [Full Text] [Related]

  • 7. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
    Liu H, Wu J, Ge Y, Li A, Li J, Liu Z, Xu Y, Xu Q, Li Y.
    Bioorg Med Chem; 2018 Mar 01; 26(5):1050-1061. PubMed ID: 29426629
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y, Li A, Wu J, Feng H, Wang L, Liu H, Xu Y, Xu Q, Zhao L, Li Y.
    Eur J Med Chem; 2017 Mar 10; 128():180-191. PubMed ID: 28182990
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K, Troiano V, Ettari R, Pinto A, Micale N, Di Giovanni C, Cerchia C, Schirmeister T, Novellino E, Lavecchia A, Zappalà M, Grasso S.
    ChemMedChem; 2014 Aug 10; 9(8):1801-16. PubMed ID: 24891205
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
    Han L, Wen Y, Li R, Xu B, Ge Z, Wang X, Cheng T, Cui J, Li R.
    Bioorg Med Chem; 2017 Aug 01; 25(15):4031-4044. PubMed ID: 28634039
    [Abstract] [Full Text] [Related]

  • 12. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
    Zhu Y, Zhu X, Wu G, Ma Y, Li Y, Zhao X, Yuan Y, Yang J, Yu S, Shao F, Li R, Ke Y, Lu A, Liu Z, Zhang L.
    J Med Chem; 2010 Mar 11; 53(5):1990-9. PubMed ID: 20158184
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
    Zhu Y, Yao S, Xu B, Ge Z, Cui J, Cheng T, Li R.
    Bioorg Med Chem; 2009 Oct 01; 17(19):6851-61. PubMed ID: 19747832
    [Abstract] [Full Text] [Related]

  • 14. Proteasome inhibitors.
    Cvek B.
    Prog Mol Biol Transl Sci; 2012 Oct 01; 109():161-226. PubMed ID: 22727422
    [Abstract] [Full Text] [Related]

  • 15. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR, Leestemaker Y, Schuurman KG, Ruggeri B, Jones-Bolin S, Williams M, Ovaa H.
    Mol Pharm; 2012 May 07; 9(5):1126-35. PubMed ID: 22432738
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
    Zhang J, Cao J, Xu L, Zhou Y, Liu T, Li J, Hu Y.
    Bioorg Med Chem; 2014 Jun 01; 22(11):2955-65. PubMed ID: 24767818
    [Abstract] [Full Text] [Related]

  • 17. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
    Zhang W, Wang X, Zhang H, Wen T, Yang L, Miao H, Wang J, Liu H, Yang X, Lei M, Zhu Y.
    Bioorg Med Chem; 2021 Jun 15; 40():116182. PubMed ID: 33971487
    [Abstract] [Full Text] [Related]

  • 18. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
    Zhou Y, Liu X, Xue J, Liu L, Liang T, Li W, Yang X, Hou X, Fang H.
    J Med Chem; 2020 May 14; 63(9):4701-4715. PubMed ID: 32267687
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
    Agyin JK, Santhamma B, Roy SS.
    Bioorg Med Chem Lett; 2013 Dec 01; 23(23):6455-8. PubMed ID: 24119559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.